Joseph A. Ware

7.0k citations
66 papers · 5.7k · 1 hit paper · h-index 28

Impact in

  • Pharmacology top 0.2%
    • Pharmacogenetics and Drug Metabolism
    • Drug-Induced Hepatotoxicity and Protection
  • Oncology top 1%
    • Drug Transport and Resistance Mechanisms

Papers in

  • Oncology 23
    • Drug Transport and Resistance Mechanisms 21
  • Genetics 11
    • Chronic Lymphocytic Leukemia Research 11
Co-authors
Hani S. Zaher (6 shared papers)Joe Palandra (4 shared papers)Rommel G. Tirona (4 shared papers)Richard B. Kim (4 shared papers)Fengmei Hua (3 shared papers)Mark P. Grillo (3 shared papers)Laurent Salphati (9 shared papers)Charles G. Knutson (3 shared papers)
Journals
Molecular Pharmaceutics (7 papers)Drug Metabolism and Disposition (6 papers)British Journal of Clinical Pharmacology (5 papers)The Journal of Clinical Pharmacology (4 papers)Chemical Research in Toxicology (3 papers)
Partner nations
United StatesCanadaUnited Kingdom

In The Last Decade

Joseph A. Ware

65 papers receiving 5.4k citations

Joseph A. Ware's Hit Papers

Membrane transporters in drug development 2010 · 2.8k citations
2.8k0+5+10Years since publication50010001.5k2.0k2.5k
What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

  1. 2010 Nature Reviews Drug Discovery

Peers

Joseph A. Ware
Comparison fields: 5 of 125
  • Pharmacology 1.0k
  • Oncology 3.0k
  • Pediatrics, Perinatology and Child Health 1.4k
  • Biochemistry 237
  • Pharmaceutical Science 195
Replace Toshiyuki Sakaeda with:
Toshiyuki Sakaeda Japan
Keith A. Hoffmaster United States
Kathleen M. Hillgren United States
Maciej J. Zamek‐Gliszczynski United States
Donald Tweedie United States
Joseph W. Polli United States
Douglas D. Ross United States
Sook Wah Yee United States
Caroline A. Lee United States
Sharyn D. Baker United States
Joseph A. Ware relative to Toshiyuki Sakaeda Japan Toshiyuki Sakaeda's profile →
Citations per field
00.5×1.5×2×2.3×
Toshiyuki Sakaeda · 1×
Citations per year

Countries citing papers authored by Joseph A. Ware

Since Specialization
Citations

This map shows the geographic impact of Joseph A. Ware's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph A. Ware with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph A. Ware more than expected).

Fields of papers citing papers by Joseph A. Ware

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph A. Ware. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph A. Ware. The network helps show where Joseph A. Ware may publish in the future.

Co-authors

The 25 scholars most cited alongside Joseph A. Ware, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joseph A. Ware Line = papers co-authored together Joseph A. Ware links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Membrane transporters in drug development
Nature Reviews Drug Discovery ·Kathleen M. Giacomini, Shiew‐Mei Huang, Donald Tweedie, Leslie Z. Benet, Kim L. R. Brouwer, Xiaoyan Chu, Amber Dahlin, Raymond Evers
Hit paper breakdown →		20102751
2
First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Clinical Cancer Research ·Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Sophie Kristeleit, Krunal Jitendrakumar Shah, Víctor Moreno, Paul Andrew Clarke, Florence I. Raynaud
2014288
3
Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)
Journal of Medicinal Chemistry ·John A. Flygare, Maureen H. Beresini, Nageshwar R. Budha, Helen Chan, Iris T. Chan, Sravanthi Cheeti, Frederick B. Cohen, Kurt D. Deshayes
2012211
4
Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development
Molecular Pharmaceutics ·Gillian S. Smelick, Timothy P. Heffron, Laura Kay Chu, Brian Dean, David A. West, Scott L. DuVall, Bert L. Lum, Nageshwar R. Budha
2013158
5
Breast Cancer Resistance Protein (Bcrp/abcg2) Is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse
Molecular Pharmaceutics ·Hani S. Zaher, Anis Ahmed Khan, Joe Palandra, Timothy G. Brayman, Linning Yu, Joseph A. Ware
2006137
6
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
Cancer Discovery ·Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Timothy Richard Wilson, Joseph A. Ware, Sandra Sanabria Bohórquez, Heidi M. Savage, Deepak Sampath
2017135
7
Curcumin Inhibits the Activity of ABCG2/BCRP1, a Multidrug Resistance-Linked ABC Drug Transporter in Mice
Pharmaceutical Research ·Suneet Shukla, Hani S. Zaher, Anika M. S. Hartz, Bjoern Bauer, Joseph A. Ware, Suresh V. Ambudkar
2008130
8
Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design
Drug Metabolism and Disposition ·Caroline A. Lee, Meeghan O'Connor, Tasha K. Ritchie, Aleksandra Galetin, Jack Cook, Isabelle Ragueneau‐Majlessi, Harma M. Ellens, Bo Feng
2015119
9
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
Clinical Cancer Research ·Saoirse Olivia Dolly, Andrew J. Wagner, Johanna C. Bendell, Hedy Lee Kindler, Lee M. Krug, Tanguy Y. Seiwert, Marjorie Glass Zauderer, Martijn P. Lolkema
2016119
10
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe
Pharmacogenetics and Genomics ·Bradley L. Urquhart, Joseph A. Ware, Rommel G. Tirona, Richard H. Ho, Brenda F. Leake, Ute I. Schwarz, Hani S. Zaher, Joe Palandra
2008115
11
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
Journal of Clinical Oncology ·Thomas Powles, Mark R. Lackner, Stéphane Marie. Oudard, Bernard J. Escudier, Christy Ralph, Janet Elizabeth Brown, Robert E. Hawkins, Daniel Castellano
2016112
12
Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium
Clinical Pharmacology & Therapeutics ·Raymond Evers, Micheline Piquette‐Miller, Joseph W. Polli, Frans G. M. Rüssel, Jason A. Sprowl, Kimio Tohyama, Joseph A. Ware, Saskia N. de Wildt
2018107
13
Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin
Molecular Pharmacology ·Hani S. Zaher, Henriette E. Meyer zu Schwabedissen, Rommel G. Tirona, Melissa L. Cox, Leslie Obert, Nidhi Kishore Agrawal, Joe Palandra, Jeffrey L. Stock
200895
14
EXPRESSION AND FUNCTION OF ABCB1 AND ABCG2 IN HUMAN PLACENTAL TISSUE
Drug Metabolism and Disposition ·Dhanashri Kolwankar, Douglas D. Glover, Joseph A. Ware, Timothy S. Tracy
200574
15
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
Clinical Cancer Research ·Harvey Wong, Laurent Vernillet, Amy C. Peterson, Joseph A. Ware, Lillian Lee, Jean‐François Martini, Peiwen Yu, Congfen Li
201272
16
STUDIES ON THE CHEMICAL REACTIVITY OF DICLOFENAC ACYL GLUCURONIDE WITH GLUTATHIONE: IDENTIFICATION OF DICLOFENAC-S-ACYL-GLUTATHIONE IN RAT BILE
Drug Metabolism and Disposition ·Mark P. Grillo, Charles G. Knutson, Phillip E. Sanders, Daniel J. Waldon, Fengmei Hua, Joseph A. Ware
200371
17
Antibody-Mediated Inhibition of Fibroblast Growth Factor 19 Results in Increased Bile Acids Synthesis and Ileal Malabsorption of Bile Acids in Cynomolgus Monkeys
Toxicological Sciences ·Rama Pai, Dorothy M. French, Ning Ma, Kathy Hötzel, Emile G. Plise, Laurent Salphati, Kenneth D.R. Setchell, Joseph A. Ware
201270
18
A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
Cancer ·Vicky Makker, Fernando O. Recio, Ling Ma, Ursula A. Matulonis, Jennifer Lauchle, Hema R. Parmar, Houston Gilbert, Joseph A. Ware
201669
19
Cyclooxygenase inhibitors increase Na-K-2Cl cotransporter abundance in thick ascending limb of Henle’s loop
American Journal of Physiology-Renal Physiology ·Patricia Fernández‐Llama, CAROLYN A. ECELBARGER, Joseph A. Ware, Peter M. Andrews, Alanna J. Lee, R. James Turner, Søren Nielsen, Mark A. Knepper
199966
20
Mechanistic Studies on the Bioactivation of Diclofenac: Identification of Diclofenac-S-acyl-glutathione in Vitro in Incubations with Rat and Human Hepatocytes
Chemical Research in Toxicology ·Mark P. Grillo, Fengmei Hua, Charles G. Knutson, Joseph A. Ware, Chunze Li
200365

About Joseph A. Ware

Joseph A. Ware is a scholar working on Oncology, Genetics, Pediatrics, Perinatology and Child Health, Pharmacology and Pharmacology, having authored 66 papers that have together received 5.7k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (21 papers), Chronic Lymphocytic Leukemia Research (11 papers), Pharmacological Effects and Toxicity Studies (11 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Inflammatory mediators and NSAID effects (4 papers), Pharmacogenetics and Drug Metabolism (4 papers), Eicosanoids and Hypertension Pharmacology (4 papers) and HIV/AIDS drug development and treatment (4 papers). The work is most often cited by research in Pharmacology (1.0k citations), Oncology (3.0k citations), Pediatrics, Perinatology and Child Health (1.4k citations), Biochemistry (237 citations) and Pharmaceutical Science (195 citations). Joseph A. Ware has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Hani S. Zaher, Joe Palandra, Rommel G. Tirona, Richard B. Kim, Fengmei Hua, Mark P. Grillo, Laurent Salphati, Charles G. Knutson, Leslie J. Dickmann and Timothy G. Brayman. Their work appears in journals such as Molecular Pharmaceutics, Drug Metabolism and Disposition, British Journal of Clinical Pharmacology, The Journal of Clinical Pharmacology and Chemical Research in Toxicology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiyuki SakaedaBreakdown of academic impact, for papers by Keith A. HoffmasterBreakdown of academic impact, for papers by Kathleen M. HillgrenBreakdown of academic impact, for papers by Maciej J. Zamek‐GliszczynskiBreakdown of academic impact, for papers by Donald TweedieBreakdown of academic impact, for papers by Joseph W. PolliBreakdown of academic impact, for papers by Douglas D. RossBreakdown of academic impact, for papers by Sook Wah YeeBreakdown of academic impact, for papers by Caroline A. LeeBreakdown of academic impact, for papers by Sharyn D. Baker